APLM (Apollomics Inc.) Price-to-Projected Revenue Ratio
Apollomics, Inc. (APLM) attracts leading oncologists through large-scale research and generous R&D funding. The expected P/S metric visualizes this intellectual potential, where the value of 6.30 characterizes this level. Monopoly prospects driven by lung cancer patents are complemented by a strategy of avoiding price wars in favor of regulatory approvals, which shapes the current trend on the chart.
APLM (apollomicsinc.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- business market valuation indicators:
- book value of equity indicators:
- debt and liquidity data:
- business earnings and investment ratios data:
APLM - Net Financial Result|Future Profit Apollomics, Inc.|APLM - Company Value to Net Income|Forward P/E Multiple Apollomics|APLM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc.|APLM - Operating profit before amortization|Net earnings per share (EPS TTM) Apollomics|APLM - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months apollomicsinc.com|APLM - Expected net earnings per share growth this year|Earnings growth forecast for next year Apollomics, Inc.
- sales revenue and business income indicators:
Analysis of all company metrics:Apollomics Corp APLM
The forward P/S reflects the market valuation of the business relative to expected sales volume, allowing for the determination of the growth premium or the risk of asset overvaluation. By analyzing the forward price-to-sales ratio, an investor can gauge the sensitivity of Apollomics, Inc. (APLM) capitalization to FDA and NMPA decisions, which directly determine the scaling pace of the oncology ecosystem and the influx of new patients.
Analysis of competing companies
Price-to-Projected Revenue Ratio BeiGene ONC|HALO (Halozyme Therapeutics, Inc.) - Future Price to Revenue|RVMD - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Ascentage Pharma Corp|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|URGN (urogen.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Bicara Therapeutics|Price-to-Projected Revenue Ratio PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|DCTH - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|AURA - Forward Price-to-Revenue Multiple|Candel - Forward P/S Multiple|Market Cap to Expected Sales Ratio Accuray Inc ARAY|SLS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Actuate Therapeutics Inc|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|TuHURA (HURA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple WHWK (Aadi Bioscience)|Market Cap to Expected Sales Ratio TScan Therapeutics Inc (TCRX)|CSBR - Price-to-Projected Revenue Ratio|XBIT (XBiotech Inc.) - Market Cap to Projected Revenue|CVM: Forward P/S Multiple|Forward Price-to-Revenue Multiple OS Therapies Inc.|Forward Price-to-Revenue Multiple RADX|Artiva (ARTV) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ANL|Forward P/S Multiple verupharma.com (VERU)|Price-to-Projected Revenue Ratio Tempest Therapeutics, Inc. TPST|XLO (Xilio Therapeutics Inc) - Future Price to Revenue|RENB - Price-to-Projected Revenue Ratio|MURA: Price-to-Projected Revenue Ratio|kairospharma.com (KAPA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Curis Corp (CRIS)|Forward P/S Multiple THAR|Forward P/S Multiple advanbiomed.com (ADVB)|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|CLDI: Market Cap to Projected Revenue|Sunshine Biopharma, Inc. - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|SLRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|Price-to-Projected Revenue Ratio American Oncology Network Inc|BGNE: Forward Price to Sales|Forward Price-to-Revenue Multiple CKPT (Checkpoint Therapeutics, Inc.)|ELEV (elevationoncology.com) - Forward Price to Sales|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|VIRX - Forward P/S Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
